Chiklita ad

Showing posts with label B-cell. Show all posts
Showing posts with label B-cell. Show all posts

Thursday, 14 September 2017

HIV vaccine breakthrough


Vaccines work by imitating an infection and setting up a memory B-cell response in advance of an actual infection. In HIV infection, the body mounts a very strong antibody response in the first few weeks that partially works, reducing the viral load from millions to thousands. However it does not control viral replication any further or eliminate HIV infection, and eventually weakens so that the viral load increases again

An effective HIV vaccine may be a short step away, scientists have overcome a major stumbling block hindering its development. The inability to generate immune cells that stay in circulation long enough to stop the virus from spreading is a big problem in providing cure for HIV.

The problem can be solved  by unblocking a process linked to an HIV protein that was preventing the production of antibody-generating B-cells from the immune system. For a vaccine to work, its effects need to be long lasting, improving B-cell responses to an HIV vaccine is the key to HIV cure. The new method produced desired immune system responses that lasted more than a year in the laboratory experiment.

Producing vaccines that stimulate long-lasting B-cell responses against HIV is the solution to HIV treatment. B-cells need time to make highly effective neutralising antibodies, but in previous studies B-cell responses were so short lived, they disappeared before they had the time to make all the changes necessary to kill HIV.
          haleplushearty.blogspot.com

Friday, 18 August 2017

Besponsa for treatment of acute lymphoblastic leukemia


Food and Drug Administration approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. ALL.

B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.

Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.

Women who are pregnant or breastfeeding should not take Besponsa because it may cause harm to a developing fetus or a newborn baby.

Side effects of Besponsa include low levels of platelets, low levels of certain white blood cells, infection, low levels of red blood cells, fatigue, severe bleeding, fever, nausea, headache, low levels of white blood cells with fever, liver damage, abdominal pain, high levels of bilirubin in the blood,
decrease in blood cell and platelet production, infusion-related reactions and problems with the heart’s electrical pulses.
          haleplushearty.blogspot.com